Tissue Regenix Group Plc Cash Flow Conversion Efficiency

Latest as of June 2025: -0.007x

Tissue Regenix Group Plc cash flow conversion efficiency. Based on the latest financial reports, Tissue Regenix Group Plc (TRX) has a cash flow conversion efficiency ratio of -0.007x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX-202.00K ≈ $-24.58 USD) by net assets (GBX28.62 Million ≈ $3.48K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Tissue Regenix Group Plc (2008–2024)

Cash flow conversion efficiency of Tissue Regenix Group Plc from 2008 to 2024. This chart illustrates how Tissue Regenix Group Plc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Tissue Regenix Group Plc (TRX) stock price for real-time trading data and today's change.

Tissue Regenix Group Plc Cash Flow Conversion Ratio Explained

Tissue Regenix Group Plc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Tissue Regenix Group Plc Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Tissue Regenix Group Plc ranked by their cash flow conversion efficiency. Also see Tissue Regenix Group Plc (TRX) market capitalisation for the company's overall valuation and market capitalisation.

Company Cash Flow Conversion Efficiency
IRPC PCL
STU:TPIG
-0.076x
Ordinary Fully Paid Deferred Settlement
AU:GMNDA
N/A
Accentro Real Estate AG
F:A4Y
0.064x
Shapeways Holdings, Inc
NASDAQ:SHPWQ
-0.202x
Edgio, Inc.
NASDAQ:EGIOQ
-0.070x
H C Slingsby PLC
LSE:SLNG
0.086x
Isomet Corp
NASDAQ:IOMT
0.073x
Ordinary Fully Paid Deferred Settlement
AU:RC1DC
N/A

Annual Cash Flow Conversion Efficiency for Tissue Regenix Group Plc (2008–2024)

The table below shows the annual cash flow conversion efficiency of Tissue Regenix Group Plc from 2008 to 2024. Review Tissue Regenix Group Plc (TRX) free cash flow to assess how much free cash flow the company generates relative to operating cash flow.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 GBX29.06 Million
≈ $3.54K
GBX-1.64 Million
≈ $-198.93
-0.056x -258.83%
2023-12-31 GBX29.36 Million
≈ $3.57K
GBX1.04 Million
≈ $126.54
0.035x +169.20%
2022-12-31 GBX25.27 Million
≈ $3.08K
GBX-1.29 Million
≈ $-157.44
-0.051x +57.57%
2021-12-31 GBX24.65 Million
≈ $3.00K
GBX-2.98 Million
≈ $-361.97
-0.121x +44.50%
2020-12-31 GBX27.85 Million
≈ $3.39K
GBX-6.05 Million
≈ $-736.72
-0.217x +24.13%
2019-12-31 GBX24.59 Million
≈ $2.99K
GBX-7.05 Million
≈ $-857.66
-0.287x -37.96%
2018-12-31 GBX32.57 Million
≈ $3.96K
GBX-6.77 Million
≈ $-823.23
-0.208x +16.10%
2018-01-31 GBX39.52 Million
≈ $4.81K
GBX-9.79 Million
≈ $-1.19K
-0.248x -0.48%
2017-12-31 GBX39.52 Million
≈ $4.81K
GBX-9.74 Million
≈ $-1.18K
-0.246x +73.43%
2016-12-31 GBX11.54 Million
≈ $1.40K
GBX-10.70 Million
≈ $-1.30K
-0.927x -121.78%
2016-01-31 GBX30.25 Million
≈ $3.68K
GBX-12.65 Million
≈ $-1.54K
-0.418x +40.36%
2015-01-31 GBX11.58 Million
≈ $1.41K
GBX-8.12 Million
≈ $-987.60
-0.701x -135.61%
2014-01-31 GBX31.30 Million
≈ $3.81K
GBX-9.31 Million
≈ $-1.13K
-0.298x -77.43%
2013-01-31 GBX38.64 Million
≈ $4.70K
GBX-6.48 Million
≈ $-788.51
-0.168x -119.91%
2012-01-31 GBX43.78 Million
≈ $5.33K
GBX-3.34 Million
≈ $-406.19
-0.076x +67.87%
2011-01-31 GBX9.84 Million
≈ $1.20K
GBX-2.34 Million
≈ $-284.20
-0.237x -139.99%
2010-01-31 GBX3.67 Million
≈ $446.11
GBX-362.65K
≈ $-44.12
-0.099x +29.53%
2009-01-31 GBX3.63 Million
≈ $442.27
GBX-510.22K
≈ $-62.08
-0.140x -144.13%
2008-01-31 GBX9.68 Million
≈ $1.18K
GBX-556.78K
≈ $-67.74
-0.057x --

About Tissue Regenix Group Plc

LSE:TRX UK Biotechnology
Market Cap
$628.37
GBX5.16 Million GBX
Market Cap Rank
#32025 Global
#1321 in UK
Share Price
GBX0.07
Change (1 day)
+0.00%
52-Week Range
GBX0.07 - GBX0.07
All Time High
GBX2162.50
About

Tissue Regenix Group plc, a medical technology company, develops and commercializes platform technologies for bone graft substitutes, skin, and soft tissue biologics markets in the United States and internationally. The company operates in two segments, dCELL and BioRinse. It offers dCELL technology, a soft tissue decellularisation process that removes DNA and other cellular material from animal … Read more